Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma

  • Angelika Tölle1Email author,
  • Saba Suhail1,
  • Monika Jung1,
  • Klaus Jung1, 2 and
  • Carsten Stephan1, 2
Contributed equally
BMC Cancer201111:302

DOI: 10.1186/1471-2407-11-302

Received: 21 February 2011

Accepted: 18 July 2011

Published: 18 July 2011

Abstract

Background

Fatty acid binding proteins (FABP) play an important role in carcinogenesis. Modified FABP expression patterns were described for prostate, bladder and for renal cell carcinoma. Studies on metabolic relationships and interactions in permanent cell lines allow a deeper insight into molecular processes. The aim of this study is therefore a systematic overview on mRNA and protein expressions of seven FABPs in frequently used urological cell lines.

Methods

Nine cell lines of renal carcinomas, seven of urinary bladder carcinomas, and five of prostate carcinomas were investigated. Quantitative RT-qPCR and western blotting were used to determine different FABPs. In addition, 46 paired cancerous and noncancerous tissue samples from nephrectomy specimen with renal cell carcinomas were investigated regarding the ileum FABP mRNA expression level and associated with survival outcome.

Results

General characteristics of all urological carcinoma cell lines were the expression of E-and IL-FABP on mRNA and protein level, while the expressions differed between the cell lines. The protein expression was not always congruent with the mRNA expression. Renal cell carcinoma cell lines showed expressions of L-, H- and B-FABP mRNA in addition to the general FABP expression in five out of the eight investigated cell lines. In bladder cancer cell lines, we additionally found the expression of A-FABP mRNA in six cell lines, while H-FABP was present only in three cell lines. In prostate cancer cell lines, a strong reduction of A- and E- FABP mRNA was observed. The expression of B-FABP mRNA and protein was observed only in the 22 RV-1 cells. IL-FABP mRNA was over-expressed in renal tumour tissue. The IL-FABP ratio was identified as an independent indicator of survival outcome.

Conclusions

Distinctly different FABP expression patterns were observed not only between the cell lines derived from the three cancer types, but also between the cell lines from the same cancer. The FABP patterns in the cell lines do not always reflect the real situation in the tumours. These facts have to be considered in functional studies concerning the different FABPs.

Background

Fatty acid binding proteins (FABPs) represent a family of cytosolic proteins containing 9 different types. The designations for the FABPs were derived from the tissue from which they had originally been isolated and include: (1) liver (L-FABP); (2) intestine (I-FABP); (3) heart (H-FABP); (4) adipocyte (A-FABP); (5) epidermis (E-FABP); (6) ileal (IL-FABP); (7) brain (B-FABP); (8) myelin (M-FABP) and (9) testis (T-FABP). The FABPs bind different fatty acids and take on the transport to cellular compartments. Thus, FABPs are involved in lipid metabolism and regulation of gene expression [1]. Recently, it has been shown that FABPs play an important role in carcinogenesis. Respective studies in solid tumours are summarised in table 1. Regarding urological tumours, modified FABP expression patterns were described for prostate [2] and urinary bladder cancer [3] as well as for renal cell carcinoma [4]. Hammamieh et al. [2] proved the influence of the FABPs on proliferation and apoptosis in prostate cancer. The loss of A-FABP expression in bladder carcinomas occurs mainly in invasive urothelial carcinomas [3] suggesting that FABPs could be used as tumour markers. In renal cell carcinomas, L- and H-FABP were decreased and B-FABP was up-regulated [4, 5].
Table 1

Investigated FABP subtypes in solid carcinomas

FABP subtypes

Solid carcinomas

liver FABP (1)

colon [15], breast [16], kidney [4], liver [17], prostate [2], stomach [18],

intestine FABP (2)

colon [19], breast [16]

heart FABP (3)

kidney [5], stomach [20]

adipocyte FABP (4)

bladder [3], breast [16, 21], prostate [2]

epidermal FABP (5)

bladder [14], breast [16], oral [22], pancreas [23], prostate [2]

ileum FABP (6)

colon [24]

brain FABP (7)

glioblastom [25, 26], kidney [4], melanoma [27, 28]

For studying metabolic relationship and interaction it is necessary to work with permanent cell lines derived from human tumours that allow a deeper insight into molecular processes. It is therefore the aim of this study to give a systematic overview on the mRNA and protein expression of seven FABPs in frequently used urological cell lines since information about FABPs in cell lines [2, 6] is scarce and incomplete. In the present study, nine cell lines of renal carcinomas, seven of urinary bladder carcinomas and five of prostate carcinomas were included and present the essential object of our investigations. IL-FABP expression on transcript level in renal cell carcinoma tissues and its prognostic value is additionally given as preliminary study for the use of FABPs in clinical research. We decided to study renal cell carcinoma as example for clinical specimens, since our group have already investigated in previous studies [4] the expression of the two FABP-types B-FABP and L-FABP in renal cell carcinomas.

Methods

Cell culture

Cell lines originating from renal cell carcinoma, bladder and prostate cancer representing the three most frequent urologic carcinomas were included in the study (Table 2). Cells purchased from American Type Culture Collection (Manassas, VA USA) and from German Collection of Microorganism and Cell Culture (Braunschweig, Germany) were cultured as described in the manufacturer's instructions. The LNCaP and SW-839 cells were cultured in Primaria flasks (Becton, Dickinson and Company, Heidelberg, Germany) and all the other cells in standard usual flasks (Becton, Dickinson and Company) maintained in a humid chamber at 37°C and 5% CO2. All cell lines except Caki-1, Caki-2, SW 839 were maintained in RPMI 1640 medium. Caki-1, Caki-2 and SW 839, ACHN and HK-2 were maintained in McCoy's 5A medium, the cell line ACHN in MEM medium and the HK-2 cells in K-SFM medium. All tissue culture media were obtained from Invitrogen GmbH (Karlsruhe, Germany) and fetal calf serum from PAA Laboratories GmbH (Pasching, Austria). The media were supplemented with antibiotics (1 × penicillin/streptomycin: 100 U/ml and 100 μg/ml, PAA Laboratories). All cells were harvested under microscopic control with a solution of 0.5 g/l trypsin plus 0.2 g/l EDTA (Invitrogen GmbH) solved in PBS and frequently washed and counted in Dulbecco's PBS from PAA Laboratories.
Table 2

Examined cell lines of urological carcinomas in this study

Renal cell carcinoma

Prostate carcinoma

Urinary bladder carcinoma

Cell line

Origin

Cell line

Origin

Cell line

Origin

786-0

Primary adenocarcinoma

BPH-1

Benign hyperplasia

HCV-29

Normal bladder irradiated

A 498

Primary tumour

DU-145

Metastasis of brain

HT-1376

Primary transitional cell carcinoma G3

A 704

Primary adenocarcinoma

LNCaP

Metastasis of lymph node

J-82

Primary transitional cell Carcinoma

ACHN

Primary adenocarcinoma

PC-3

Metastasis of bone marrow

RT-4

Primary transitional cell carcinoma T2,G1

Caki-1

Clear cell carcinoma Metastasis of skin

22 RV-1

Primary tumour

RT-112

Primary transitional Cell carcinoma G2

Caki-2

Primary clear cell carcinoma

  

SCaBER

Primary squamous Cell carcinoma

HK-2

Normal tissue proximal tubule

  

UM-UC-3

Primary transitional cell carcinoma

SN-12

Primary tumour

    

SW 839

Primary tumour

    

Tumour material and clinico-pathological data of patients

Forty-six matched (malignant and non-malignant) kidney specimens from primary tumours were used for total RNA isolation. The samples were derived from patients with renal cell carcinomas (RCC) undergoing radical tumour nephrectomy at the Department of Urology, Charité - Universitätsmedizin Berlin, Germany between 2003 and 2005. Staging met the UICC 2002 criteria. Histological classification was performed according to the WHO criteria; tumour grading was accomplished according to Fuhrman. The clinico-pathological parameters in all RCC were summarised in table 3. The endpoint of the survival analyses was the cancer-related survival measured from the date of the radical nephrectomy to the time of the last follow-up or death. This study has been approved by the Charité University Ethics Committee.
Table 3

Clinico-pathological characteristics of the study cohort of patients with renal cell carcinomas

  

Total

Clear cell

RCC

papillary

RCC

Other**

RCC

All cases

 

46

36

2

8

Age, years*

 

40 - 78

   

Median*

 

61.0

   

Sex

male

35

   
 

female

11

   

Grading

G1

3

3

  
 

G2

30

27

2

1

 

G3

11

6

 

5

 

G4

2

  

2

pT State

pT1a

6

6

  
 

pT1b

8

6

 

2

 

pT2

2

2

  
 

pT3a

11

8

 

3

 

pT3b

15

11

2

2

 

pT3c

2

2

  
 

pT4

2

1

 

1

Metastasis

M0

27

24

1

2

 

M1

19

12

1

6

Lymph nodes

N0

14

14

  
 

N1

9

4

2

3

 

NX

23

18

 

5

* Values are given as range and median

** This group involves six sarcomatoide, one mixed form (clear cell/papillary) and one Ductus Bellini carcinoma

RNA isolation from cells and tissue samples

The total RNA from cells and tissue material were isolated using the RNeasy mini Kit from Qiagen (Qiagen GmbH, Hilden, Germany). The cell number was adjusted between 2 and 6 × 106 cells. All preparation steps were performed according to the supplier's protocol. The sample pairs from the same kidney were collected immediately after surgery in RNAlater® Stabilization Reagent (Qiagen, Hilden, Germany), stored overnight at 4°C and at -80°C afterwards. The RNA isolation was performed as formerly described by our group [4] and resulted in RNA samples with an absorbance of 260/280 nm ratio in the range from 1.96 to 2.08 and RNA integrity values of 9.7 ± 0.8 (mean ± SD) for renal, of 9.9 ± 0.22 for prostate and of 10.0 ± 0.08 for bladder cell lines as well as of 8.4 ± 1.02 for tissue samples.

Real-Time PCR

One μg RNA of the various urological cell lines and of the kidney tissues respectively, was reverse transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany) by random hexamer priming method according to the manufacturer's recommendations. The detailed procedure was previously described [4]. All used primers and probes were summarised in table 4.
Table 4

Sequences of primer sets and UPL probes

Gene

Accession number

Primer

Sequences (5'...3')

Product size[bp]

UPL probe*

L-FABP1

NM_001443

Forward

ttctccggcaagtaccaact

93

72

  

Reverse

cttccccttctggatgagc

  

I-FABP2

NM_000134

Forward

acaacctagcagacggaactg

78

1

  

Reverse

tccgtttgaattttccaataagtt

  

H-FABP3

NM_004102

Forward

ctgggcacctggaagcta

77

56

  

Reverse

ctggtagcaaaacccacacc

  

A-FABP4

NM_001442

Forward

cctttaaaaatactgagatttccttca

105

72

  

Reverse

ggacacccccatctaaggtt

  

E-FABP5

NM_001444

Forward

gcagacccctctctgcac

138

56

  

Reverse

tcgcaaagctattcccactc

  

IL-FABP6

NM_001445

Forward

ctcagagatcgtgggtgaca

68

22

  

Reverse

tcacgcgctcataggtca

  

B-FABP7

NM_001446

Forward

ctcagcacattcaagaacacg

69

33

  

Reverse

ccatccaggctaacaacagac

  

TBP

NM_003194

Forward

ttcggagagttctgggattgta

227

 
  

Reverse

tggactgttcttcactcttggc

  
   

Probe:

F-ccgtggttcgtggctctcttatcctcaT-P

  

PPIA

NM_021130

Forward

Hs_PPIA_I_SG

121

 
  

Reverse

QuantiTect Primer Assay

  
   

Qiagen

(Cat. No. QT00052311)

  

* UPL probes from Universal ProbeLibrary; Roche

The previously characterised conditions [4] were used for all materials and for all FABP types except A-FABP, for which an annealing temperature of 58°C for 20 s was preferred. For relative quantification of FABP mRNA expression, we also determined the two genes TATA box-binding protein (TBP) and peptidylproline isomerase A (PPIA) verified in a previous study as most suitable reference genes for gene profiling studies in renal cell carcinoma tissue [7]. Standard curves were generated for all gene-specific PCRs with cDNA samples from cell lines or tissues to calculate gene expression and PCR efficiencies that were between 1.85 and 2.01. The specificity of PCR was checked by the length of PCR products using agarose gel electrophoresis (Figure 1). All samples were measured in duplicates. The intraserial run precision (n = 9) of the PCR measurements, measured by the determination of IL-FABP amounted to a variation coefficient of 6.62% at a mean concentration of 2.66 × 10-2 (Cq-value of 26.09).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-11-302/MediaObjects/12885_2011_Article_2819_Fig1_HTML.jpg
Figure 1

A submarine agarose gel electrophoresis for PCR product control. The PCR amplificates run in 3% (w/v) agarose, small DNA low melt (Biozym, Oldendorf, Germany) in TBE buffer pH 8 and ethidium bromide (0.5 μg/ml).

Protein extraction and western blot analysis

Suspensions of 2 - 3 × 107 cells were washed two times in PBS and then sedimented by 300 × g centrifugation for 10 min. Cell lysates were prepared according to the method of Zigrino et al. [8]. Protein extraction of paired tissue samples (carcinoma/normal) from six nephrectomy specimens was carried out as described by Fritzsche et al. [9]. All protein extracts were run under reducing conditions in a 15% SDS-polyacrylamide gel. Western blot analysis was carried out using the standard protocol for protein transfer onto PVDF membrane (Millipore Corp, Bedford, MA, USA) according to Towbin et al. [10]. Western blotting was performed with FABP type specific antibodies as summarised in table 5. Actin served as loading control. The antigen-antibody reaction was visualized by ECL Advance™ Western Blotting Detection Kit (GE Healthcare UK Limited, Little Chalfont Buckinghamshire, UK). Intensity of the detected signals by Western blot was quantified with Fluor-S MultiImager (Bio-Rad Laboratories, Hercules, USA).
Table 5

Antibodies for Western Blot detection

Protein

Species

 

Supplier

Concentration

L-FABP

Rabbit IgG

polyclonal

Hycult biotechnology b.v., Uden, Netherlands

1 μg/ml

I-FABP

Rabbit IgG

polyclonal

Hycult biotechnology b.v., Uden, Netherlands

2 μg/ml

H-FABP

Mouse IgG1

monoclonal

Clone 66E2

Hycult biotechnology b.v., Uden, Netherlands

1 μg/ml

A-FABP

Rabbit IgG

polyclonal

Hycult biotechnology b.v., Uden, Netherlands

0.2 μg/ml

E-FABP

Rabbit IgG

polyclonal

Hycult biotechnology b.v., Uden, Netherlands

0.1 μg/ml

IL-FABP

Rabbit IgG

polyclonal

Hycult biotechnology b.v., Uden, Netherlands

1 μg/ml

B-FABP

Rabbit IgG

polyclonal

Hycult biotechnology b.v., Uden, Netherlands

1 μg/ml

β-actin

Mouse IgG2

monoclonal

Clone AC-74

Sigma-Aldrich Chemie GmbH, Munich, Germany

2.1 μg/ml

anti-rabbit IgG/HRP*

Goat

polyclonal

DakoCytomation, Glostrup, Denmark

0.12 μg/ml

anti-mouse IgG/HRP*

Rabbit

polyclonal

DakoCytomation, Glostrup, Denmark

0.53 μg/ml

* HRP - Horseradish peroxidase

Statistical analysis

Statistical analysis was performed with SPSS, version 19.0 (SPSS Inc, Chicago, IL, USA). P values < 0.05 were considered significant.

Results

FABP expression on transcript and protein levels in cell lines

The general characteristic of all urological carcinoma cell lines is the expression of E-and IL-FABP both on mRNA and protein level (Figure 2A-C), while the expressions differed between the cell lines. In addition, in all cell lines studied neither the I-FABP protein nor the I-FABP mRNA was detectable.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-11-302/MediaObjects/12885_2011_Article_2819_Fig2_HTML.jpg
Figure 2

FABP subtype mRNA expression in the various carcinoma cell lines. (A) Renal cell carcinoma cell lines; (B) Urinary bladder carcinoma cell lines; (C) Prostate carcinoma cell lines. P labelled the immunoblot detection of FABP and P* marked a very strong immunoblot detection of FABP.

Renal cell carcinoma cell lines

The cell line HK-2 derived from normal renal tissue only expressed mRNAs of E-FABP and IL-FABP. Its mRNA expression pattern differed in comparison to the five carcinoma cell lines 786-0, A 704, ACHN, Caki-1 and Caki-2, which showed additional FABPs. The 786-0 and Caki-1 cells expressed L-FABP, ACHN cells expressed H-FABP and A 704 and Caki-2 cells expressed B-FABP.

The protein expression was not always congruent with the mRNA expression and the levels of E- and IL-FABP in these cells were different in the cell lines. In 786-0, A 498 and Caki-2 cells, the E-FABP protein expression was very high (Figure 3A). Caki-2 cells were characterised also by a high IL-FABP level. All the other mRNAs except B-FABP in Caki-2 cells (Figure 2A) were not transcribed to the corresponding protein that was not detectable at all.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-11-302/MediaObjects/12885_2011_Article_2819_Fig3_HTML.jpg
Figure 3

Western blot detection of FABP subtypes in various carcinoma cell lines. Exemplary protein detection in (A) renal carcinoma cells in (B) urinary bladder carcinoma cells and in (C) prostate carcinoma cells.

Urinary bladder carcinoma cell lines

E- and IL-FABP were ubiquitously detectable as mRNA and protein in all bladder cell lines (Figure 2B). The protein expression level was increased in the carcinoma lines in comparison to normal bladder cell line HCV-29 (Figure 3B). The carcinoma cell lines were characterised by the two additional H- and A-FABP mRNAs. The mRNA and protein expression was not always congruent. The HT-1376, J-82 and SCaBER cells expressed A-FABP mRNA, but the protein was not detectable. The situation for the H-FABP mRNA was similar. The highest A-FABP mRNA expression was observed in RT-4 and RT-112 cells and here the protein was also detectable (Figure 3B).

Prostate carcinoma cell lines

E-FABP was found to be the main FABP in prostate carcinoma cell lines (Figure 2C), while the LNCaP cell lines showed the lowest mRNA expression and the protein expression was lacking (Figure 3C). The expression of IL-FABP mRNA was lower compared to the E-FABP mRNA. The protein detection of IL-FABP was positive in all cell lines, but distinct intensity differences were observed. In DU-145 and 22 RV-1 cells, the protein content was lower than in the other cell lines (Figure 3C).

The benign prostate hyperplasia cell line (BPH-1) was characterised by the two additional mRNAs of H-FABP and A-FABP. Two cell lines derived from metastasis, DU-145 and LNCaP, lost of these two mRNAs (H-FABP and A-FABP). The 22 RV-1 cells, derived from a primary prostate carcinoma, were marked by the loss of A-FABP mRNA and appearance of B-FABP mRNA and the corresponding protein. Protein detection of H- and A-FABP was not possible in all cell lines, so that differences between mRNA and protein expression appeared there, too.

IL-FABP mRNA expression in RCC tissue

The expression of IL-FABP in normal and tumour tissues were normalised against the geometric mean expression of the two reference genes PPIA and TBP. The increase of IL-FABP in the tumour tissues was calculated as relation of normalised concentration in tumour tissue to normalised concentration in normal tissue and further on mentioned as ratio. The IL-FABP mRNA expression was 137-times higher (median) in RCC than in the normal tissue (p < 0.0001; Figure 4). The IL-FABP ratio was not correlated to the tumour grade and stage (rs = -0.143, p = 0.343; rs = -0.181, p = 0.228). Samples from patients without metastasis at the time of radical nephrectomy (27 cases) displayed a 139-fold (median) over-expression (Figure 4), while samples from nephrectomised patients with metastases showed 116-fold (median) over-expression (Figure 4). This difference was not significant (p = 0.219).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-11-302/MediaObjects/12885_2011_Article_2819_Fig4_HTML.jpg
Figure 4

IL-FABP ratio in a cohort of patients with renal cell carcinoma. The IL-FABP ratio was calculated as relation of normalised IL-FABP mRNA concentration in tumour tissue to normalised concentration in normal tissue. Expression data were normalised against the geometric means of the two reference genes PPIA and TBP. The median of IL-FABP ratio was calculated for all patients, for Patients without metastasis (M0) and for patients with metastasis (M1): Statistical differences were calculated by the Mann Whitney test.

IL-FABP expression and patient survival time

The tumour cohort studied was representative because the conventional prognostic parameters (tumour stage, tumour grade and metastasis) reached significance for survival in Kaplan-Meier analysis (Figure 5). Patients with high-stage, high-grade tumours and with metastasis had a lower cancer-related survival time. Taking all patients together, the IL-FABP ratio in the tumour tissue was not associated with the survival time (log rank test, p = 0.194). However, differences were found when the two subgroups of patients with and without metastasis at the date of radical nephrectomy were separately analysed. In patients without metastasis, no association was found between the IL-FABP ratio and the survival time (log-rank test, p = 0.755). In contrast, in the group of patients with distant metastases (M1; n = 19), an increased ratio of IL-FABP in the malignant compared with the non-malignant tissue sample was significantly associated with a longer survival time (log-rank test, p = 0.004; Figure 5C). Using the multivariable Cox regression analysis with the variables pT stage, grade, metastasis and the mentioned IL-FABP ratio, IL-FABP arose as independent variable (log-rank test, p = 0.029). This result was internally validated with a bootstrap analysis with 5000 bootstrap replicates and the 95% percentile approach. The independence of the variable IL-FABP ratio was confirmed (log-rank test, p = 0.026).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-11-302/MediaObjects/12885_2011_Article_2819_Fig5_HTML.jpg
Figure 5

Kaplan-Meier survival curves for IL-FABP mRNA expression in matched RCC tissue samples. (A) Fuhrman grades 1 and 2 compared to 3 and 4, (B) Tumour stage pT1 and pT2 (tumour is limited to the kidney) compared to pT3 and pT4 (tumour extends over the organ), (C) Patients without metastasis (M0) compared to those with metastasis (M1), (D) IL-FABP ratio above and below the median was compared for all cases, (E) IL-FABP ratio above and below the median was compared in the group of patients without metastasis (M0), (F) IL-FABP ratio above and below the median was compared in the group of patients with metastasis (M1).

Discussion

Approximately one quarter of all newly diagnosed cancer patients have urological tumours [11]. Thus, the purpose to improve early diagnosis and to introduce new reliable therapies for these cancer patients is a main objective of urological research. It is based on the search for characteristic tissue markers that can be used not only as diagnostic and/or prognostic biomarkers but also as targets for new treatment strategies. In this respect, the altered expression of FABPs in solid tumours and especially in urological tumours is of great interest as briefly discussed in the section Background (Table 1). The observation of altered expression is to be verified under experimental conditions and it is necessary to work with well described permanent cell lines relating to the FABP expression. To the best of our knowledge we present in this study the first systematic investigation concerning the expression of most FABPs in urological cell lines.

Our data show three essential features: (a) the expression of E- and IL-FABP and the lack of expression of I-FABP on mRNA and protein levels in all urological cell lines (Figure 2A-C), (b) the inconsistent congruence between the mRNA expression and protein expression differing both between the various FABPs and the cell lines as described in detail in the section Results and (c) the different patterns of FABPs not only between but also within the organ-specific cell lines.

Discrepancies between RNA and protein could be explained by different analytical sensitivities of the methods, in case of RT-PCR and Western blot technique, and more probably, by biological reasons. As extensive cellular machinery is involved in the process of translation, possible differences between RNA and protein expression can be caused by posttranscriptional regulatory mechanisms. These processes are still poorly understood. One possibility is that small non-coding RNAs might influence the translation.

In addition to the general expression of E- and IL-FABP in all cell lines, five out of the eight investigated renal cell carcinoma cell lines showed expressions of L-, H- and B-FABP mRNA. Only the Caki-2 cells represented the situation in renal cell carcinoma tissue, particularly the decreased or absent expression of L- and H-FABP and the up-regulation of B-FABP mRNA. Protein of B-FABP was exclusively detectable in the Caki-2 cells. It was known from earlier studies [4, 5] that renal tumour tissue showed reduced expression levels of L-FABP and H-FABP and increased B-FABP compared to normal renal tissues.

The results of IL-FABP expression and our previous observations regarding the clinical significance of B- and L-FABPs in renal cell carcinoma [4] prompted us to examine IL-FABP mRNA expression in matched malignant and non-malignant specimens from kidney after radical nephrectomy. IL-FABP mRNA was over-expressed in the tumour tissue and no statistical differences were observed between samples from patients with and without metastases at the date of surgery. However, it was remarkable that patients with metastasis and an increased IL-FABP mRNA ratio showed a longer survival time. The IL-FABP ratio was identified as an independent indicator for survival outcome. Along with the retrospective nature of this study, the low number of patients was a limitation of this investigation. However, the internal validation using a bootstrap approach proved this result despite the low number of patients investigated. Therefore, we consider this as preliminary result that would be worth to be confirmed in further studies. Patients with high grade tumours and metastasis have a poor prognosis. In this group, a high IL-FABP expression might be an advantage because the transport of fatty acids could be enhanced. It is a speculation that cells incorporate a large amount of long-chain polyunsaturated fatty acids and so the level of antioxidants could be increased in the cells. This could be a protection against elevated ROS level in cancer cells.

In summary, this and the former study showed that the renal cell carcinoma tissue was characterised by decreased L- and H-FABPs and increased B- and IL-FABPs. The changes of these four FABP types indicate fundamental alterations in the fatty acid metabolism in the RCC carcinogenesis. Most of the investigated renal carcinoma cell lines only partly reflected these changes in tumour tissue.

In bladder cancer cell lines, we found in addition to the general expression of E- and IL-FABP the expression of A-FABP in six examined cell lines, while H-FABP was present only in three cell lines (HT-1376, J-82, SCaBER). A high expression of A-FABP mRNA and protein was observed in the well-differentiated RT-4 and RT-112 cells, while the other cell lines, which had been derived from less-differentiated, high-grade bladder tumours such as HT-1376 cells showed lower A-FABP mRNA expression. This result corresponds to data of Ohlsson et al. [3] and Boiteux et al. [12] who described the loss of A-FABP as marker for bladder cancer progression. On the other hand, the E-FABP mRNA expression in the HT-1376 cells, derived from a poorly differentiated G3 tumour [13], was higher than in the well-differentiated RT-112 cells, whereas Ostergaard et al. [14] reported a decreased expression of E-FABP in less-differentiated tumours. Thus, this result also supports the conclusion that the expression in the cells does not always reflect the situation in tumours.

The expression pattern of various FABP types in prostate cancer cell lines was previously described by Das et al. [6]. The authors observed a strong reduction of A-, E- and H-FABP in the cancer cell lines LNCaP, DU-145, and PC-3 compared to cells from normal primary cell cultures. The present work proved this result for A- and E-FABP in comparison to the BPH-1 cells derived from benign prostate hyperplasia. We observed in androgen-sensitive LNCaP cells a more than 1500-fold lower expression of E-FABP than in androgen-insensitive BPH-1. The expression of B-FABP mRNA and protein was observed only in the 22 RV-1 cells derived from a primary tumour. Das et al. [6] observed B-FABP in LNCaP cells and in prostate cancer tissues of well-differentiated tumours and suggested B-FABP as stage-specific marker in prostate cancer. L-and I-FABP were not detected in the present study at all. LNCaP cells were characterised by IL-FABP and a low expression of E-FABP mRNA.

Conclusions

Our study is the first report about the mRNA and protein expression of various FABP types in frequently used cell lines from prostate, bladder, and kidney cancers. Regarding to carcinoma cell lines, distinct differences of FABP expression patterns were observed between the cells derived from the three cancer types but also between the organ-specific cell lines. In addition, the FABP patterns in the cell lines do not reflect the real situation in the tumours. It was suggested that in normal tissues a balance exists between different FABP types and that this balance is destroyed in cancerogenesis causing a new composition of FABP types [6]. To study this effect in more detail, the knowledge on the FABP expression as given in this study might be helpful in selecting an appropriate cell line for experimental work.

Notes

Declarations

Acknowledgements

This work was supported by grants from the European Regional Development Fund (EFRE), ProFIT grant no. 10140618. We are grateful to Silke Klotzek and Ines Baumert for excellent technical assistance.

Authors’ Affiliations

(1)
Department of Urology, Charité - Universitätsmedizin Berlin
(2)
Berlin Institute for Urologic Research

References

  1. Boord JB, Fazio S, Linton MF: Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol. 2002, 13: 141-147. 10.1097/00041433-200204000-00005.View ArticlePubMedGoogle Scholar
  2. Hammamieh R, Chakraborty N, Das R, Jett M: Molecular impacts of antisense complementary to the liver fatty acid binding protein (FABP) mRNA in DU 145 prostate cancer cells in vitro. J Exp Ther Oncol. 2004, 4: 195-202.PubMedGoogle Scholar
  3. Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE: Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics. 2005, 4: 570-581. 10.1074/mcp.M500017-MCP200.View ArticlePubMedGoogle Scholar
  4. Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, et al: Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?. BMC Cancer. 2009, 9: 248-10.1186/1471-2407-9-248.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, et al: Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics. 2005, 5: 2631-2640. 10.1002/pmic.200401264.View ArticlePubMedGoogle Scholar
  6. Das R, Hammamieh R, Neill R, Melhem M, Jett M: Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clin Cancer Res. 2001, 7: 1706-1715.PubMedGoogle Scholar
  7. Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, et al: In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol. 2007, 8: 47-10.1186/1471-2199-8-47.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Zigrino P, Mauch C, Fox JW, Nischt R: Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer. 2005, 116: 853-859. 10.1002/ijc.21087.View ArticlePubMedGoogle Scholar
  9. Fritzsche FR, Jung M, Tölle A, Wild P, Hartmann A, Wassermann K, et al: ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. Eur Urol. 2008, 54: 1097-1106. 10.1016/j.eururo.2007.11.034.View ArticlePubMedGoogle Scholar
  10. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979, 76: 4350-4354. 10.1073/pnas.76.9.4350.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.View ArticlePubMedGoogle Scholar
  12. Boiteux G, Lascombe I, Roche E, Plissonnier ML, Clairotte A, Bittard H, et al: A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer. 2009, 124: 1820-1828. 10.1002/ijc.24112.View ArticlePubMedGoogle Scholar
  13. Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA, Arnstein P: Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst. 1977, 58: 881-890.PubMedGoogle Scholar
  14. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, et al: Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res. 1997, 57: 4111-4117.PubMedGoogle Scholar
  15. Lawrie LC, Dundas SR, Curran S, Murray GI: Liver fatty acid binding protein expression in colorectal neoplasia. Br J Cancer. 2004, 90: 1955-1960. 10.1038/sj.bjc.6601828.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Hammamieh R, Chakraborty N, Barmada M, Das R, Jett M: Expression patterns of fatty acid binding proteins in breast cancer cells. J Exp Ther Oncol. 2005, 5: 133-143.PubMedGoogle Scholar
  17. Keler T, Sorof S: Growth promotion of transfected hepatoma cells by liver fatty acid binding protein. J Cell Physiol. 1993, 157: 33-40. 10.1002/jcp.1041570105.View ArticlePubMedGoogle Scholar
  18. Hashimoto T, Kusakabe T, Watanabe K, Sugino T, Fukuda T, Nashimoto A, et al: Liver-type fatty acid-binding protein is highly expressed in intestinal metaplasia and in a subset of carcinomas of the stomach without association with the fatty acid synthase status in the carcinoma. Pathobiology. 2004, 71: 115-122. 10.1159/000076465.View ArticlePubMedGoogle Scholar
  19. Davidson NO, Ifkovits CA, Skarosi SF, Hausman AM, Llor X, Sitrin MD, et al: Tissue and cell-specific patterns of expression of rat liver and intestinal fatty acid binding protein during development and in experimental colonic and small intestinal adenocarcinomas. Lab Invest. 1993, 68: 663-675.PubMedGoogle Scholar
  20. Hashimoto T, Kusakabe T, Sugino T, Fukuda T, Watanabe K, Sato Y, et al: Expression of heart-type fatty acid-binding protein in human gastric carcinoma and its association with tumor aggressiveness, metastasis and poor prognosis. Pathobiology. 2004, 71: 267-273. 10.1159/000080061.View ArticlePubMedGoogle Scholar
  21. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM: Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat. 2009Google Scholar
  22. Fang LY, Wong TY, Chiang WF, Chen YL: Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J Oral Pathol Med. 2010, 39: 342-348.View ArticlePubMedGoogle Scholar
  23. Sinha P, Hutter G, Köttgen E, Dietel M, Schadendorf D, Lage H: Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis. 1999, 20: 2952-2960. 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
  24. Ohmachi T, Inoue H, Mimori K, Tanaka F, Sasaki A, Kanda T, et al: Fatty acid binding protein 6 is overexpressed in colorectal cancer. Clin Cancer Res. 2006, 12: 5090-5095. 10.1158/1078-0432.CCR-05-2045.View ArticlePubMedGoogle Scholar
  25. Kaloshi G, Mokhtari K, Carpentier C, Taillibert S, Lejeune J, Marie Y, et al: FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol. 2007, 84: 245-248. 10.1007/s11060-007-9377-4.View ArticlePubMedGoogle Scholar
  26. Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R: B-FABP-expressing radial glial cells: the malignant glioma cell of origin?. Neoplasia. 2007, 9: 734-744. 10.1593/neo.07439.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, et al: A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res. 2006, 66: 4443-4449. 10.1158/0008-5472.CAN-05-2505.View ArticlePubMedGoogle Scholar
  28. Slipicevic A, Jorgensen K, Skrede M, Rosnes AK, Troen G, Davidson B, et al: The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer. 2008, 8: 276-10.1186/1471-2407-8-276.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/302/prepub

Copyright

© Tölle et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.